메뉴 건너뛰기




Volumn 87, Issue 2, 2010, Pages 166-174

Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: Focus on cardiac repolarization (QTc interval)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[10 (2 HYDROXYETHOXY) 9 ANTHRYL]METHYLAMINO] 2 METHYL 1,3 PROPANEDIOL; 2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ACLARUBICIN; ACODAZOLE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; COMBRETASTATIN A4 PHOSPHATE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DEPSIPEPTIDE; ENZASTAURIN; IXABEPILONE; L 778123; LAPATINIB; LONAFARNIB; NILOTINIB; PANOBINOSTAT; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; ROMIDEPSIN; S 59788; SR 271425; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VANDETANIB; VORINOSTAT; ZL 647;

EID: 75749147526     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.214     Document Type: Review
Times cited : (37)

References (25)
  • 1
    • 49749147563 scopus 로고    scopus 로고
    • Both EGfR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels
    • Zhang, D.Y., Wang, Y., Lau, C.P., Tse, H.F. & Li, G.R. Both EGfR kinase and Src-related tyrosine kinases regulate human ether-à-go-go- related gene potassium channels. Cell Signal. 20, 1815-1821 (2008).
    • (2008) Cell Signal. , vol.20 , pp. 1815-1821
    • Zhang, D.Y.1    Wang, Y.2    Lau, C.P.3    Tse, H.F.4    Li, G.R.5
  • 2
    • 75749120735 scopus 로고    scopus 로고
    • Experience in QT evaluation of oncology drug products since ICH E14 guidance. Proceedings of 2008 american Society of Clinical Oncology annual Meeting
    • May 20 suppl. abstract 2554
    • Liu, Q., Madabushi, R., Garnett, C. & Booth, B. Experience in QT evaluation of oncology drug products since ICH E14 guidance. Proceedings of 2008 american Society of Clinical Oncology annual Meeting, J. Clin. Oncol. 26 (May 20 suppl.), (2008). abstract 2554
    • (2008) J. Clin. Oncol. , vol.26
    • Liu, Q.1    Madabushi, R.2    Garnett, C.3    Booth, B.4
  • 3
    • 33745725793 scopus 로고    scopus 로고
    • Cardiac safety, risk management, and oncology drug development
    • fingert, H.J. & Varterasian, M.L. Cardiac safety, risk management, and oncology drug development. Clin. Cancer Res. 12, 3646-3647 (2006).
    • (2006) Clin. Cancer Res. , vol.12 , pp. 3646-3647
    • Fingert, H.J.1    Varterasian, M.L.2
  • 4
    • 34548276036 scopus 로고    scopus 로고
    • Molecularly targeted oncology therapeutics and prolongation of the QT interval
    • Strevel, E.L., Ing, D.J. & Siu, L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J. Clin. Oncol. 25, 3362-3371 (2007).
    • (2007) J. Clin. Oncol. , vol.25 , pp. 3362-3371
    • Strevel, E.L.1    Ing, D.J.2    Siu, L.L.3
  • 5
    • 35348925070 scopus 로고    scopus 로고
    • Evaluation of the efect on cardiac repolarization (QTc interval) of oncologic drugs
    • Morganroth, J. Evaluation of the efect on cardiac repolarization (QTc interval) of oncologic drugs. Ernst Schering Res. Found. Workshop 59, 171-184 (2007).
    • (2007) Ernst Schering Res. Found. Workshop , vol.59 , pp. 171-184
    • Morganroth, J.1
  • 6
    • 40249094483 scopus 로고    scopus 로고
    • Drug-induced QTc interval prolongation: A proposal towards an efcient and safe anticancer drug development
    • Curigliano, G. et al. Drug-induced QTc interval prolongation: a proposal towards an efcient and safe anticancer drug development. Eur. J. Cancer 44, 494-500 (2008).
    • (2008) Eur. J. Cancer , vol.44 , pp. 494-500
    • Curigliano, G.1
  • 7
    • 44949175102 scopus 로고    scopus 로고
    • Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents
    • Sarapa, N. & Britto, M.R. Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin. Drug Saf. 7, 305-318 (2008).
    • (2008) Expert Opin. Drug Saf. , vol.7 , pp. 305-318
    • Sarapa, N.1    Britto, M.R.2
  • 8
    • 64349093768 scopus 로고    scopus 로고
    • Assessing proarrhythmic potential of drugs when optimal studies are infeasible
    • Rock, E.P. et al. assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am. Heart J. 157, 827-36, 836.e1 (2009).
    • (2009) Am. Heart J. , vol.157
    • Rock, E.P.1
  • 9
    • 75749156715 scopus 로고    scopus 로고
    • The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals
    • Committee for Medicinal Products for Human Use. ICH Note for Guidance on EMEa, London, 25 May
    • Committee for Medicinal Products for Human Use. ICH Note for Guidance on "The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals" (ICH S7B) (CHMP/ICH/423/02) EMEa, London, 25 May 2005.
    • (2005) (ICH S7B) (CHMP/ICH/423/02)
  • 11
    • 36749056453 scopus 로고    scopus 로고
    • HERG channel trafcking: Novel targets in drug-induced long QT syndrome
    • Dennis, a., Wang, L., Wan, X. & ficker, E. hERG channel trafcking: novel targets in drug-induced long QT syndrome. Biochem. Soc. Trans. 35, 1060-1063 (2007)
    • (2007) Biochem. Soc. Trans. , vol.35 , pp. 1060-1063
    • Dennis, A.1    Wang, L.2    Wan, X.3    Ficker, E.4
  • 12
    • 54849435649 scopus 로고    scopus 로고
    • Inhibition of hERG channel trafcking: An under-explored mechanism for drug-induced QT prolongation
    • yeung, K.S. & Meanwell, N.a. Inhibition of hERG channel trafcking: an under-explored mechanism for drug-induced QT prolongation. ChemMedChem. 3, 1501-1502 (2008).
    • (2008) Chem Med Chem. , vol.3 , pp. 1501-1502
    • Yeung, K.S.1    Meanwell, N.A.2
  • 13
    • 50049083789 scopus 로고    scopus 로고
    • The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes
    • Carlsson, L. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. Pharmacol. Ther. 119, 160-167 (2008)
    • (2008) Pharmacol. Ther. , vol.119 , pp. 160-167
    • Carlsson, L.1
  • 14
    • 48149111313 scopus 로고    scopus 로고
    • Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts
    • Sugiyama, A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br. J. Pharmacol. 154, 1528-1537 (2008).
    • (2008) Br. J. Pharmacol. , vol.154 , pp. 1528-1537
    • Sugiyama, A.1
  • 15
    • 33644823249 scopus 로고    scopus 로고
    • Amplifcation of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes
    • Antzelevitch, C. & Oliva, a. amplifcation of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes. J. Intern. Med. 259, 48-58 (2006).
    • (2006) J. Intern. Med. , vol.259 , pp. 48-58
    • Antzelevitch, C.1    Oliva, A.2
  • 16
    • 21344463329 scopus 로고    scopus 로고
    • Refning detection of drug-induced proarrhythmia: QT interval and TRIaD
    • Shah, R.R. & Hondeghem, L.M. Refning detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2, 758-772 (2005)
    • (2005) Heart Rhythm , vol.2 , pp. 758-772
    • Shah, R.R.1    Hondeghem, L.M.2
  • 17
    • 48149096544 scopus 로고    scopus 로고
    • Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model
    • yao, X. et al. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br. J. Pharmacol. 154, 1446-1456 (2008).
    • (2008) Br. J. Pharmacol. , Issue.154 , pp. 1446-1456
    • Yao, X.1
  • 18
    • 44349105190 scopus 로고    scopus 로고
    • Evaluating the QT-liability of a drug during its development
    • Shah, R.R. & Morganroth, J. Evaluating the QT-liability of a drug during its development. Pharm. Med. 22, 151-164 (2008).
    • (2008) Pharm. Med. , vol.22 , pp. 151-164
    • Shah, R.R.1    Morganroth, J.2
  • 19
    • 0025825919 scopus 로고
    • Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia
    • Morganroth, J., Brozovich, F.V., McDonald, J.T. & Jacobs, R.A. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am. J. Cardiol. 67, 774-776 (1991).
    • (1991) Am. J. Cardiol. , vol.67 , pp. 774-776
    • Morganroth, J.1    Brozovich, F.V.2    McDonald, J.T.3    Jacobs, R.A.4
  • 20
    • 0141576728 scopus 로고    scopus 로고
    • Baseline heart rate-corrected QT and eligibility for clinical trials in oncology
    • Varterasian, M. et al. Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J. Clin. Oncol. 21, 3378-3379 (2003).
    • (2003) J. Clin. Oncol. , vol.21 , pp. 3378-3379
    • Varterasian, M.1
  • 21
    • 75749138651 scopus 로고    scopus 로고
    • Risk management and eligibility criteria for QTc assessment in patients with advanced cancer. Proceedings of 2005 american Society of Clinical Oncology annual Meeting
    • (June 1 suppl.), 16S, Part I of II (2005). abstract 3047
    • Sarapa, N., Huang, X., Varterasian, M. & fingert, H. Risk management and eligibility criteria for QTc assessment in patients with advanced cancer. Proceedings of 2005 american Society of Clinical Oncology annual Meeting, J. Clin. Oncol. 23 (June 1 suppl.), 16S, Part I of II (2005). abstract 3047
    • J. Clin. Oncol. , vol.23
    • Sarapa, N.1    Huang, X.2    Varterasian, M.3    Fingert, H.4
  • 22
    • 34247580900 scopus 로고    scopus 로고
    • QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines
    • Arbel, y., Swartzon, M. & Justo, D. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines. Anticancer Drugs 18, 493-498 (2007).
    • (2007) Anticancer Drugs , vol.18 , pp. 493-498
    • Arbel, Y.1    Swartzon, M.2    Justo, D.3
  • 23
    • 0029883856 scopus 로고    scopus 로고
    • Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug efect from spontaneous variability
    • Pratt, C.M. et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug efect from spontaneous variability. Am. Heart J. 131, 472-480 (1996).
    • (1996) Am. Heart J. , vol.131 , pp. 472-480
    • Pratt, C.M.1
  • 24
    • 39749192587 scopus 로고    scopus 로고
    • The diagnosis and management of cardiovascular disease in cancer patients
    • Yusuf, S.W., Razeghi, P. & yeh, E.T. The diagnosis and management of cardiovascular disease in cancer patients. Curr. Probl. Cardiol. 33, 163-196 (2008).
    • (2008) Curr. Probl. Cardiol. , vol.33 , pp. 163-196
    • Yusuf, S.W.1    Razeghi, P.2    Yeh, E.T.3
  • 25
    • 33645728030 scopus 로고    scopus 로고
    • Promise of new vascular-disrupting agents balanced with cardiac toxicity: Is it time for oncologists to get to know their cardiologists?
    • Van Heeckeren, W.J. et al. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J. Clin. Oncol. 24, 1485-1488 (2006).
    • (2006) J. Clin. Oncol. , vol.24 , pp. 1485-1488
    • Van Heeckeren, W.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.